Infections in People With Lymphoma or Myeloma Treated With Bispecific Antibodies
Follows adults with blood cancers on bispecific antibodies to see how often infections occur.
Plain-language title generated from the registry record
Registry title: Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.
Key facts
- Where
- Madrid, SpainSee the 2 sites
Where in Spain
- Infanta Leonor University HospitalMadrid, SpainTaking people
- University Hospital Infanta LeonorMadrid, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Infanta Leonor University Hospital
- Trial code
- NCT07609576
- Record updated
- 27 May 2026
- Original description
This is a prospective, multicenter, observational cohort study involving patients with hematologic malignancies who are receiving bispecific antibody therapy. The primary objective of this study is to evaluate the incidence, type, and severity of infectious complications in hematologic patients undergoing treatment with bispecific antibodies.Read full original descriptionShow less
Multicenter Study Proposal: Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.
This is a prospective, multicenter, observational cohort study involving patients with hematologic malignancies who are receiving bispecific antibody therapy. The primary objective of this study is to evaluate the incidence, type, and severity of infectious complications in hematologic patients undergoing treatment with bispecific antibodies.
Secondary objectives include identifying risk factors associated with infection, comparing infectious outcomes across different hematologic malignancies and BsAb types, and assessing the impact of infections on overall treatment outcomes.
Inclusion: Adult patients (≥18 years) diagnosed with hematologic malignancies (e.g., multiple myeloma, non-Hodgkin lymphoma) who are receiving treatment with bispecific antibodies; Patients must have initiated BsAb therapy within 30 days prior to study enrollment; Ability to provide informed consent; Severe infections will be recorded the first year, but infectious events past confirmed relapse or new treatments for the underlying disease will not be recorded.